The Alzheimer's Drug Discovery Foundation's (ADDF) formally announced an award of funding to Cogstate from the ADDF Diagnostics Accelerator (DxA) initiative, which is a partnership of funders including ADDF Co-Founder Leonard Lauder, Bill Gates, Jeff Bezos and Mackenzie Bezos, the Dolby family, and the Charles and Helen Schwab Foundation, among others, seeking to develop novel biomarkers for the early detection of Alzheimer's disease and related dementias. The up to $1.3 million award to Cogstate will be focused on the development of a technology-based approach for early detection of memory impairment and decline. Under the terms of the funding arrangement, ADDF will reimburse Cogstate for technical development costs, as well as costs of scientific validation studies. The funding will be made available in a number of tranches subject to Cogstate's compliance with periodic reporting and other requirements (including progress towards achieving the goals of the project). Cogstate will fund the balance of the costs required to deliver the project. Following successful technology development and commercial release, Cogstate will pay ADDF a royalty of 4% on the first $150 million of revenue generated by the smart-phone application and 2.5% on all revenue thereafter, up to a cap of $11.6 million of total royalty payments. Chris Edgar, Ph.D., Senior Vice President of Clinical Science at Cogstate. The technology adaptation will be purpose designed to enable autonomous assessment of memory by individuals in their own home. Improved access to such an easy-to-use and sensitive measure of memory is expected to enable identification of memory problems earlier and in more diverse populations, thereby supporting earlier diagnosis and access to potential interventions. An estimated 50 million people worldwide are currently living with Alzheimer's disease or other dementias, a figure that will almost triple by 2050. Memory decline is one of the earliest signs of the disease, and memory assessments are an important, early component of diagnosis. Testing for memory impairment requires a face- to-face visit with a trained and experienced neuropsychologist able to administer a formal memory test. This approach has drawbacks in terms of patient burden and access to care. Further, patients are often evaluated at only a single time-point, when repeated testing over time may be more sensitive and effective at identifying problems in people with different memory abilities. The ISLT is an established test of memory developed by Cogstate, which uses a real-world scenario of trying to remember a grocery list. The test has been designed for use in multiple languages and cultures and for repeat testing over time to identify changes in memory.